News Release

Journal Article Cites Cleanascite™ for Purification of Monoclonal Antibody used in Prostate Cancer Research

MONMOUTH JUNCTION, NJ, November 14, 2023 -- Biotech Support Group reports on a journal research article describing the simplicity and efficiency of their lipid clarification technology for purifying a monoclonal antibody from ascites fluid.

The citation is:

Testa, Anna, et al. "TARGETING THE αVβ3/NgR2 PATHWAY IN NEUROENDOCRINE PROSTATE CANCER." Matrix Biology (2023).

Highly aggressive, metastatic, neuroendocrine prostate cancer, is associated with limited treatment options and hence poor prognosis. The authors have previously demonstrated that the αVβ3 integrin is over-expressed in neuroendocrine prostate cancer. They now show that LM609, a monoclonal antibody that specifically targets the human αVβ3 integrin, hinders the growth of neuroendocrine prostate cancer patient-derived xenografts in vivo. The article states “LM609 purification was performed as previously described. Briefly, LM609 ascites was cleaned with Cleanascite …, and recirculated over a Protein A column.” The report offers a better understanding of integrin-directed signaling and cell-cell communication during cancer progression. Furthermore, the results pave the way for new diagnostic and therapeutic perspectives for patients affected by neuroendocrine prostate cancer.

“While many other uses of Cleanascite™ are now common, here it is employed for one of its first intended applications, to efficiently clear lipids from ascites fluid, to assist in the purification of monoclonal antibodies.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information visit: Cleanascite™ Lipid Removal Reagent and Clarification, at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm

Keywords

Monoclonal antibody, ascites, lipid clarification, Cleanascite™.

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for expanding proteomic analysis. Following a tiered business strategy, the company continues its growth in the consumable research products area. For this market, key products include: AlbuVoid™ and AlbuSorb™ PLUS for albumin & IgG depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NRicher™ for low abundance and family specific proteome enrichment. For more information, go to http://www.biotechsupportgroup.com

For business development contact: Matthew Kuruc
732-274-2866 mkuruc@biotechsupportgroup.com